Regeneron Pharmaceuticals Q3 Adj. EPS $20.07 Beats $16.19 Estimate, Sales $5.116B Beat $4.542B Estimate
Regeneron Pharmaceuticals (NASDAQ:REGN) reported quarterly earnings of $20.07 per share which beat the analyst consensus estimate of $16.19 by 23.97 percent. This is a 69.65 percent increase over earnings of $11.83 per
Share
Why It Matters
Regeneron made way more money than people expected this quarter. When a company beats big like this, it shows the business is doing really well.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.